Cargando…

Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer

BACKGROUND: Changing the neoadjuvant chemotherapy regimen in insufficiently responding breast cancer is not a standard policy. We analysed a series of patients with ‘luminal'-type breast cancer in whom the second half of neoadjuvant chemotherapy was selected based on the response to the first h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rigter, L S, Loo, C E, Linn, S C, Sonke, G S, van Werkhoven, E, Lips, E H, Warnars, H A, Doll, P K, Bruining, A, Mandjes, I A, Vrancken Peeters, M J, Wesseling, J, Gilhuijs, K G, Rodenhuis, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3859944/ https://www.ncbi.nlm.nih.gov/pubmed/24149178 http://dx.doi.org/10.1038/bjc.2013.661

Ejemplares similares

Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer
por: Loo, Claudette E., et al.
Publicado: (2016)

The Relevance of Breast Cancer Subtypes in the Outcome of Neoadjuvant Chemotherapy
por: Straver, M. E., et al.
Publicado: (2010)

Additional value of (18)F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer
por: van Ramshorst, Mette S., et al.
Publicado: (2017)

Monitoring tumor response to neoadjuvant chemotherapy using MRI and (18)F-FDG PET/CT in breast cancer subtypes
por: Schmitz, Alexander M. Th., et al.
Publicado: (2017)

Prognostic value of breast MRI characteristics before and during neoadjuvant endocrine therapy in patients with ER+/HER2- breast cancer
por: Ragusi, Max AA, et al.
Publicado: (2021)

Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response
por: Lips, E. H., et al.
Publicado: (2013)

Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer
por: Groen, Emma J., et al.
Publicado: (2021)

Minimally Invasive Complete Response Assessment of the Breast After Neoadjuvant Systemic Therapy for Early Breast Cancer (MICRA trial): Interim Analysis of a Multicenter Observational Cohort Study
por: van Loevezijn, Ariane A., et al.
Publicado: (2020)

Contralateral parenchymal enhancement on breast MRI before and during neoadjuvant endocrine therapy in relation to the preoperative endocrine prognostic index
por: Ragusi, Max A. A., et al.
Publicado: (2020)

Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival
por: van der Voort, Anna, et al.
Publicado: (2022)

BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer
por: Liefaard, M. C., et al.
Publicado: (2023)

Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol
por: van Loevezijn, Ariane A., et al.
Publicado: (2022)

Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients
por: Straver, Marieke E., et al.
Publicado: (2010)

High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial
por: Vliek, Sonja, et al.
Publicado: (2023)

Feasibility of radioguided occult lesion localization of clip-marked lymph nodes for tailored axillary treatment in breast cancer patients treated with neoadjuvant systemic therapy
por: Hellingman, Daan, et al.
Publicado: (2019)

Enrichment of high-grade tumors in breast cancer gene expression studies
por: van Seijen, M., et al.
Publicado: (2017)

Breast Cancer Subtype Specific Classifiers of Response to Neoadjuvant Chemotherapy Do Not Outperform Classifiers Trained on All Subtypes
por: de Ronde, Jorma J., et al.
Publicado: (2014)

Contralateral parenchymal enhancement on MRI is associated with tumor proteasome pathway gene expression and overall survival of early ER+/HER2-breast cancer patients
por: Ragusi, Max A.A., et al.
Publicado: (2021)

Local staging of ipsilateral breast tumor recurrence: mammography, ultrasound, or MRI?
por: Walstra, Coco J. E. F., et al.
Publicado: (2020)

An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients
por: Vollebergh, M. A., et al.
Publicado: (2011)

Deep (phospho)proteomics profiling of pre- treatment needle biopsies identifies signatures of treatment resistance in HER2(+) breast cancer
por: Debets, Donna O., et al.
Publicado: (2023)

Ongoing Remission Nineteen Years after High-dose Chemotherapy for Oligometastatic Breast Cancer; What Can We Learn from this Patient?
por: Steenbruggen, Tessa G, et al.
Publicado: (2015)

Impact of Second Opinions in Breast Cancer Diagnostics and Treatment: A Retrospective Analysis
por: Heeg, E., et al.
Publicado: (2019)

[(18)F]FDG-PET/CT in prone compared to supine position for optimal axillary staging and treatment in clinically node-positive breast cancer patients with neoadjuvant systemic therapy
por: van Loevezijn, Ariane A., et al.
Publicado: (2021)

Factors affecting the value of diffusion-weighted imaging for identifying breast cancer patients with pathological complete response on neoadjuvant systemic therapy: a systematic review
por: van der Hoogt, Kay J. J., et al.
Publicado: (2021)

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers
por: Lips, E H, et al.
Publicado: (2013)

ASO Author Reflections: The Pursuit of Eliminating Surgery after Neoadjuvant Systemic Therapy in Breast Cancer Patients
por: van Loevezijn, Ariane A., et al.
Publicado: (2020)

MRI to assess response after neoadjuvant chemotherapy in breast cancer subtypes: a systematic review and meta-analysis
por: Janssen, L. M., et al.
Publicado: (2022)

Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer
por: Steenbruggen, Tessa G, et al.
Publicado: (2021)

Reliability of preoperative breast biopsies showing ductal carcinoma in situ and implications for non-operative treatment: a cohort study
por: Mannu, Gurdeep S., et al.
Publicado: (2019)

Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy
por: Vollebergh, Marieke A, et al.
Publicado: (2014)

Volumetric breast density estimation on MRI using explainable deep learning regression
por: van der Velden, Bas H. M., et al.
Publicado: (2020)

Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness
por: Lips, Esther H, et al.
Publicado: (2011)

Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial
por: Geurts, V.C.M., et al.
Publicado: (2023)

Evaluation of the EGFR polymorphism R497K in two cohorts of neoadjuvantly treated breast cancer patients
por: Sobral-Leite, Marcelo, et al.
Publicado: (2017)

Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy
por: Gonzalez-Angulo, A M, et al.
Publicado: (2015)

Synchronous Breast Cancer: Phenotypic Similarities on MRI
por: Wang, Hui, et al.
Publicado: (2019)

Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study
por: Balmativola, D., et al.
Publicado: (2014)

Biopsy-Guided Pathological Response Assessment in Breast Cancer is Insufficient: Additional Pathology Findings of the MICRA Trial
por: van Hemert, Annemiek K. E., et al.
Publicado: (2023)

Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome
por: Faneyte, I F, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_460hbqn5qme3m6qj4jmbsf582t